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Background: Young age at first full-term pregnancy (FFTP) is an important factor in breast cancer risk reduction. It 
is postulated that this protective effect is the result of stable molecular signatures imprinted by physiological 
process of pregnancy, but the molecular mechanism of this protective role is unclear. The aim of the current study 
was to identify the effect of early FFTP on methylation status of FOXA1 gene body. FOXA1 is an essential 
transcription factor for mammary gland development and estrogen responsiveness of breast tissue. Methods: 
Fresh frozen normal breast tissues (n = 51) were collected from Iranian women who underwent cosmetic 
mammoplasty (27 nulliparous women and 24 parous women who have experienced first pregnancy before the 
age of 25). DNA was extracted and then methylated DNA immunoprecipitation (MeDIP) real-time PCR was used to 
assess FOXA1 gene body methylation. Results: Our results revealed that FOXA1 methylation level is significantly 
higher in early parous compared with nulliparous group (p = 0.041). Conclusion: Our study provides new hint 
about the association between early FFTP and epigenetic modifications within gene body of FOXA1 in normal 
breast tissue. More investigation is required for clarifying molecular mechanisms underlying this association in 
order to develop breast cancer prevention strategies. DOI: 10.29252/.23.2.99 
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reast cancer is the most common cancer in 
women worldwide. This malignancy has 
various risk factors that are divided into 
modifiable and non-modifiable factors. An early first 
full-term pregnancy (FFTP) is the most effective 
modifiable and natural prevention method against 




The first documented scrutiny of this preventive 
performance was conducted by Bernardino Ramazzini, 
the father of industrial medicine, in 18
th
 century. He 
noted that “the nuns are found with breast tumors more 
than any other women”, and he deduced this because 
nuns remain celibate and childless in their lifetime
[2]
. 
Major evidence that displayed a correlation between 
parity and decreased breast cancer risk was through 
MacMahon et al.'s
[1]
 research, in which they carried 
out an international collaborative case-control study. 
They found that pregnancy at early age associates with 
protection against breast cancer. Women who 
B 
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experienced their first pregnancy before 20 years of 
age had a 50% reduced risk of breast cancer compared 
with nulliparous women
[1]
. Postponing first delivery 
after 35 years of age had a 23% increased breast cancer 
risk
[3]
. The early pregnancy protective effect is 
predominantly against estrogen receptor (ER) positive 
breast tumors
[4]
 and this protection is negligible for 
first gestations, which occur between the age of 30 to 
34 years
[1,5,6]
. A lot of epidemiological studies have 
shown that further gestations and breastfeeding 
increase the mentioned protective effect
[7-9]
. It is 
important to consider this protection because most 
women in different countries, especially in Western 
communities, have been shown to remain nullipara or 
to postpone the first pregnancy till the age of 35
[10,11]
. 
Therefore, the recognition of possible molecular 
mechanisms involved in protective effect of pregnancy 
will stimulate the advancement of new cancer 
prevention strategies.  
Several animal models studies have revealed that 
physiological process of early FFTP can induce 
particular molecular signatures in normal breast tissue. 
Researchers have demonstrated that these molecular 
changes play an important role in full differentiation of 
mammary glands and finally result in lifelong breast 
cancer prevention
[12-16]
. In addition to the complete 
differentiation of breast tissue, it has been suggested 
that FFTP protective effect may occur through three 
ways, including parity-specific changes in the levels of 
circulating hormones, reduction in the number of 
mammary stem cells, and variation in response to 
estrogen in normal breast tissue
[4]
. Despite extensive 
studies, the molecular mechanisms of parity-associated 
protective effect remain unclear. The lifelong breast 
cancer protection requires persistent molecular changes 
in the genome of mammary cells; hence, we 
hypothesize that epigenetic alterations, which are 
stable and permanent, may play a role in pregnancy-
associated protective effect. A previous survey has 
revealed that the breast epithelial nuclei of 
postmenopausal parous women are small and 
heterochromatic with the high level of histone 
methylation, as compared to nulliparous females
[12]
. 
Therefore, since 2014, researchers have focused on the 
investigation of parity-associated epigenetic alterations 
in the breast tissue of human and mice. For instance, 
Ghosh et al.
[17]
 have studied the epigenetic 
modifications of the normal breast tissue and found 
some parity-specific hypermethylated and hypo-
methylated genes. FOXA1 was an important 
hypermethylated gene among their findings.  
FOXA1 is a pioneer transcription factor for 
mammary gland development and has a significant 
function in the biology of luminal epithelial cells of the 
breast tissue
[18,19]
, also it is critical for the  
complete function of ERα, which is essential for 
hormone responsiveness of mammary tissue
[18,20]
.  
It has been shown that FOXA1 co-occupies  
ERα enhancers in the genome and regulates the 
expression of ERα downstream target genes
[18,21]
. It  
has also been explained that the lack of FOXA1 




In a preliminary research, we revealed the significant 
association between ESR1 methylation and some 
reproductive factors such as FFTP in breast tumors
[23]
. 
Since molecular status and molecular interactions in 
tumor tissues can be modified by malignancy process, 
which finally result in differences between malignant 
and normal tissues, in the next step, we evaluated this 
association in normal breast tissue with a different 
quantitative methylation assay, methylated DNA 
immunoprecipitation (MeDIP). According to our 
results, there was no relation between FFTP and ESR1 
methylation levels in normal breast tissue
[24]
. 
Therefore, in the current study, we focused on FOXA1 
as an upstream regulator of ER function, and the 
methylation status of FOXA1 gene was investigated in 
normal breast tissue specimens of early parous and 
nulliparous women, in order to identify specifically the 




MATERIALS AND METHODS 
 
Samples collection and DNA extraction 
 In this cross-sectional study, 51 normal breast tissue 
samples were collected from women who were 
mammoplasty candidates without a positive history of 
breast cancer or other forms of malignant diseases. The 
present work was approved by the local Ethical 
Committee of Tehran University of Medical Sciences 
(Tehran, Iran), and all participants signed the informed 
consent form. They also filled out a questionnaire 
regarding age, BMI (kg/m
2
), reproductive factors (the 
age at FFTP, number of pregnancies, breastfeeding 
duration), as well as medical and smoking history. 
Fresh frozen normal breast tissues were collected from 
Mehr-e-Sina Surgical Center, Sohrevardi Surgery 
Center, and Vali-e-Asr Clinic in Imam Khomeini 
Hospital in Tehran. Samples were divided into  
two groups: parous (n = 24) and nulliparous women  
(n = 27) and were stored at -80 °C, until DNA 
extraction was accomplished. Genomic DNA was 
extracted using the high salt method
[25]
. Isolated DNA 
was used as a template for MeDIP-quantitative 
polymerase chain reaction (qPCR) process. 
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                         Table1. Primer sequences for real-time PCR 
Gene Primers sequence Product size (bp) 
H19 (positive control) 
F: 5'- CAGGTCGGGCATTATCCAC-3' 





GAPDH (negative control) 
F: 5'- CCACATCGCTCAGACACCAT-3' 











MeDIP real-time qPCR 
 MeDIP was carried out using Methylamp
TM
 
Methylated DNA capture kit )Epigentek, USA, Cat. No 
# P-1015). After extraction, DNA (1 μg) was sheared 
by sonication to obtain fragments ranging from 200 to 
1000 bp. DNA was denatured at 95 °C for 5 minutes 
and was then divided into input (IN) and 
immunoprecipitated fractions. The immunoprecipitated 
fraction was incubated with anti-5
′
-Methylcytosine 
monoclonal antibody at room temperature for 1 hour 
and subsequently, was washed twice with 150 μl of 
antibody buffer and then with wash buffer. Finally, 
DNA was eluted from the column according to the kit 
instructions. Quality control of MeDIP and relative 
fold enrichment was performed by qPCR reaction 
using TAKARA SYBR Premix Ex Taq II (Tli Plus) 
(USA, Cat. No: RR820Q) by Corbett rotor gene 6000 
cycler (Corbett Life Science, USA). To carry out these 
steps, two pairs of primers were designed to detect 
CpG islands of H19 imprinted control region (which is 
methylated) and GAPDH promoter (an unmethylated 
housekeeping gene) as MeDIP positive and negative 
controls, respectively (Table1). URPD online software 
(http://bio.kuas.edu.tw/urpd/) was employed to design 
the primers. The thermal cycling started with an initial 
step at 95 °C for 40 seconds to activate the hot-start 
DNA polymerase.  Subsequently, a two-step cycling 
profile was done as follows: 40 cycles of annealing/ 
extension at 95 °C for 15 seconds and 60 °C for 35 
seconds. To confirm the amplification of the PCR 
target region, the amplification step was followed by a 
melting cycle from 70 °C to 99 °C (Fig. 1). Serial 
dilution analysis was performed on different DNA 
concentrations to calculate the PCR efficiency, and the 
slope of the standard curve reactions (Fig. 2). Samples 
were tested in duplicate, and non-template control 
(NTC) samples (no template control; all reagents were 
used in qPCR except DNA) were also used in all 
reactions to rule out contamination. Finally, fold-
enrichment ratio and specificity for each sample were 
calculated. When specificity was higher than 95% and 
fold-enrichment ratio exceeded 25
[26]
, MeDIP was 
considered successful. 
After accomplishing quality control for MeDIP, the 
enriched DNA fragments in MeDIP were quantified for 
target gene (FOXA1) by real-time qPCR (Tables 2).  
The primer sequences are shown in Table1, and  
Figure 3 shows the location of FOXA1-amplified 
region. Real-time PCR assay was performed in 
duplicate reactions and in the total volume of 20 μl. 
The thermal conditions of qPCR reaction were as 
follows: 95°
 
C for 40 s, 95 °C for 15 s, 60 °C for 35 s 
(40 cycles). Relative enrichment of target locus was 
normalized by positive control (H19 gene) and 
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Fig. 2. Standard curve for (A) H19 (methylated control gene), (B) GAPDH (un-methylated control gene), and (C) FOXA1 (target 
gene) real-time PCR assay for evaluating the reaction efficiency by serial dilutions of DNA (the reaction efficiency was acceptable). 
  
                  
Statistical analysis  
 Data were represented by median and interquartile 
range or frequency and percentage. Non-parametric 
Mann-Whitney U test was used to compare FOXA1 
relative methylation between early parous and 
nulliparous groups. Kruskal-Wallis test was applied to 
investigate association between FOXA1 methylation 
with breastfeeding duration and BMI. The association 
between FOXA1 methylation and other factors (age, 
smoking, and number of pregnancies) were analyzed 
by Mann-Whitney U test. Moreover, non-parametric 
spearman correlation test was employed to calculate 
the correlation between FOXA1 methylation and both 
age and breastfeeding durations. All analyzes were 
done by IBM SPSS Statistics version 22. Two tailed p 





 In this study, we used qPCR following MeDIP to 
compare FOXA1 gene body methylation levels in 
normal breast tissue of early parous with nulliparous 
women. The MeDIP fold enrichment ratio and the 
specificity for all samples were in acceptable range; the 
means of them were 14663 and 98%, respectively, 
showing that MeDIP was performed successfully, and 




    Table 2. Comparison of mean ∆ct values of control gene (H19) against unmethylated control gene (GAPDH) and target gene 




H19 mean ∆ct value  
(IP)  
(ct H19IP–ct GAPDHIP) 
H19 mean ∆ct value 
 (IN) 
(ct H19IN–ct GAPDH IN) 
FOXA1 mean ∆ct value 
(IP) 
(ct FOXA1IP–ct H19IP) 
FOXA1 mean ∆ct value 
(IN) 
(ct FOXA1IN–ct H19IN) 
Parous (n = 24) -9.63 0.88 4.15 2.98 
     
Nulliparous (n = 27) -7.94 0.66 6.18 3.96 
In MeDIP technique for each reaction, DNA was sonicated into fragments ranging in size from 200-1000 bp and was divided into 
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Fig. 3. Graphical representation of FOXA1 primers position. Primers are located in intron1 (reverse strand; +73 to +2262 relative to 
TSS). Amplified part contains eight gene body CpG sites (+1877, +1894, +1903, +1934, +1941, +1956, +1993, and +2002 relative to 
TSS)[17].  The two CPG islands sequences were extracted from University of California, Santa Cruz UCSC. TSS, transcription start 
site; E, exon. 
 
 
more than GAPDH, as an unmethylated control gene. 
 The first group was early parous women (n = 24; 
mean age = 36.37 years) who had experienced their 
first full-term pregnancy under 25 years, and the 
second group was nulliparous women (n = 27; mean 
age = 31.92 years) who had never experienced 
pregnancy. All participants in this study were cancer-
free Iranian women. The differences in methylation 
levels of studied subgroups are presented in Table 3. 
According to Whitney U test results, it was found that 
FOXA1 relative methylation level in parous group is 
significantly higher than nulliparous (p = 0.041), as 
indicated in Figure 4. Median of FOXA1 methylation 
in parous group was around twofold higher than 
nulliparous women (parous and nulliparous women 
median = 0.53 and 0.28, respectively). 
 
 
                  Table 3. Relative methylation levels among subgroups of study  
Variables Number (%) 
Relative methylation levels 
Median Q1-Q3 p value 
Parity status     
     Early parous 








     
Age (year)     
     <40 








     
BMI (kg/m2)     
     <25 
     25-30 











     
Breastfeeding duration (month)     
     Non-breastfed 
     ≤12  
     12-24  














     
Number of full term pregnancies     
     1 delivery 








     
Smoking     
     Yes 








p value in bold represents a significant difference in the methylation level of the target regions between/among 
subgroups. Q: interquartile range 
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Fig 4. Comparison of FOXA1 gene body methylation between 
parous and nulliparous groups. FOXA1 methylation was 
significantly higher in parous group compared with nulliparous 
(p = 0.041). 
 
 
We found no association of reproductive 
(breastfeeding duration and number of deliveries) and 
non-reproductive factors (BMI, age, and smoking) with 
FOXA1 gene body methylation; the results of these 
analyses are displayed in Table 3. Moreover, we did 
not observe any correlation between FOXA1 
methylation and both age and breastfeeding duration 





 Early age at FFTP is a known modifiable and a 
natural protective factor against breast cancer in 
women worldwide. Although this phenomenon was 
recognized many years ago
[1]
, the exact molecular 
mechanisms underlying this effect has remained 
unclear. Researchers hope to prevent or postpone the 
breast cancer in women at risk such as nulliparous 
women by some molecular interventions. This 
prevention policy requires discovering and 
understanding molecular changes that occur with early 
parity in normal breast tissue of women and lead to 
breast cancer protection. 
 DNA methylation is a kind of epigenetic change that 
can be inducible and stable with a strong link to 





. Hence, it is possible that these lifelong 
epigenetic alterations, which are influenced by 
women’s lifestyle, can play a crucial role in the 
protective effect of pregnancy
[27]
. According to 
previous studies, the effect of early pregnancy on 
hormone responsiveness of breast tissue, especially 
estrogen hormone, is one of the proposed mechanisms 
of parity-associated breast cancer protection
[4]
. 
Therefore, we assume that studying the effects of  
early parity on some genes such as ESR1 and  
FOXA1, which have important functions in estrogen 
responsiveness
[18]
, can improve the better 
understanding of underlying mechanisms of early 
pregnancy associated with breast cancer protective 
effect.  
In our two previous studies, we showed that ESR1 
methylation status has a significant association with 
FFTP in the breast tumors, but we did not find this 
association in normal breast tissues
[23,24]
. This result is 
consistent with the notion that the malignancy process 
can affect molecular status in tumor cells and make 
them different from normal cells. Following these 
investigations, in the present study, we decided to 
focus on the influence of early pregnancy on FOXA1 
gene methylation, which is an upstream regulator of 
ERS1 gene. Evidence from one study on normal breast 
tissue samples of a small group of American women 
(19 parous vs. 16 nulliparous) has shown the 
association of early FFTP with gene body 
hypermethylation of FOXA1 by MBD-Cap 
technique
[17]
. In the current study, for investigating 
these new findings in a different larger study 
population, we evaluated 51 normal breast tissue 
samples of Iranian women with another quantitative 
epigenetic method (MeDIP-qPCR), which is more 
efficient for the investigation of gene body methylation 
in comparison with MBD-Cap method
[28]
. Our findings 
demonstrated that early parity has significant 
correlation with gene body hypermethylation of 
FOXA1. This finding is compatible with the results 
from the previous study
[17]
.  
FOXA1 is a pioneer transcription factor that co-
localizes with ERα at enhancers in the genome and also 
is essential for ERα’s function
[18]
. This gene has high 
expression levels in luminal progenitor cells of the 
normal breast tissue, and their epigenetic status can be 
modified by early pregnancy
[19,29]
. Moreover, it has 
been shown that early parity is related to FOXA1 
epigenetic modification in epigenome mammary of 
mouse models
[30]
. In this case, researchers have shown 
that epigenetic modifications increase in FOXA1 gene 
during mice gestation, which in turn correlates with 
down-regulation of FOXA1 mRNA expression
[30]
. 
Thus, according to these findings
[30]
, which are in line 
with our results, it seems that FOXA1 gene 
hypermethylarion is a new candidate epimark that is 
modified by early pregnancy in normal breast tissue. 





 and its influence on 
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methylation status of FOXA1 gene (as an upstream 
regulator of ERα)
[18]
, it can be hypothesized that early 
pregnancy may change estrogen responsiveness of 
normal mammary tissue and result in protection against 
breast cancer.   
Epidemiological studies have shown that 
reproductive factors such as prolonged breastfeeding 
duration and increased number of births can lead to 
reduction in the risk of breast cancer
[7-9]
. Hence, we 
attempted to investigate whether these reproductive 
factors could alter FOXA1 gene body methylation in 
normal breast tissue or not. Regarding our results, there 
was no association between these factors and FOXA1 
methylation levels. It seems that the protective effect of 
lactation and the increased number of births against 
breast cancer do not act through the same molecular 
mechanisms of early FFTP.  
Based on our results, non-reproductive factors such 
as BMI, age, and smoking do not have any significant 
association with FOXA1 methylation. It seems that 
non-reproductive factors cannot influence the 
epigenetic status of FOXA1 gene in normal breast 
tissue. However, regarding our limited sample size, 
these results should be interpreted with caution and are 
required to be clarified in future investigations with a 
larger sample size. 
In conclusion, it seems that early parity, as an 
important breast cancer protective factor, can induce 
epigenetic changes in normal breast tissue. Also, all 
protective reproductive factors perhaps do not have 
similar effect on epigenetic status of normal breast 
tissue and may reduce the risk of breast cancer through 
different mechanisms. Our study provides a new hint 
about the association between early FFTP and 
epigenetic alterations within gene body of FOXA1 in 
normal breast tissue. Because of limited sample size 
and lack of FOXA1 expression analysis in this 
research, more investigation is needed to clarify the 
molecular mechanisms underlying this association with 
the aim of identifying promising new ways to advance 
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